Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Cochrane on Oral vs IV Chemotherapy for CRC
Cochrane; 2017 Jul 28; Chionh, Lau, Yeung, et al
Oral fluoropyrimidines work just as well as IV fluoropyrimidines for colorectal cancer, according to a Cochrane review of 44 trials involving more than 23,000 individuals.
In patients given curative therapy:
- Disease-free and overall survival did not differ between those receiving either oral or IV therapy.
- Patients who received either treatment had a similar risk of diarrhea.
- Those who received oral treatment were more likely to develop hand and foot rash.
- They were less likely to have neutropenia.
In those who received palliative chemotherapy:
- Overall, oral treatment led to worse progression-free survival.
- Use of 2 oral therapy formulations (UFT or Ftorafur, and eniluracil with oral 5-fluorouracil) also led to worse progression-free survival.
- 3 other oral therapy formulations (capecitabine, S-1, and doxifluridine) produced progression-free survival similar to IV treatment.
- Overall survival rates did not differ.
- Patients who received oral treatment were more likely to develop diarrhea and hand and foot rash.
- They were less likely to have lowered white cell counts.
Chionh F, Lau D, Yeung Y, Price T, Tebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database of Systematic Reviews. 2017, Issue 7. Art. No.: CD008398. doi:10.1002/14651858.CD008398.pub2.
This Week's Must Reads
Must Reads in Colon and Rectal
Fiber Intake and Survival After CRC Diagnosis, JAMA Oncol; ePub 2017 Nov 2; Song, Wu, et al
Cochrane on Detecting CRC in Patients with IBD, Cochrane; 2017 Sep 18; Bye, Nguyen, Parker, et al
Statins and Survival in Patients with Cancer, JAMA Oncol; ePub 2017 Aug 22; Emilsson, et al
Cochrane on Oral vs IV Chemotherapy for CRC, Cochrane; 2017 Jul 28; Chionh, Lau, Yeung, et al
Inflammation, Sarcopenia Impact on CRC Survival , JAMA Oncol; ePub 2017 Aug 10; Cespedes Feliciano, et al